This randomized phase 2 trial aims to establish which agent, infliximab versus intravenous immunoglobulin, may lead to greatest benefit as pneumonitis treatment for patients receiving PD-1/PD-L1 therapy
This phase II trial by EA's Cancer Control and Survivorship Committee is comparing two promising pneumonitis treatments for patients receiving PD-1/PD-L1 therapy